(3E)-3-[(4-anilino-2-methylsulfinylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[(4-anilino-2-methylsulfonylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[[4-anilino-2-[[morpholin-4-yl(phenyl)methyl]amino]pyrazolo[1,5-a][1,3,5]triazin-8-yl]methylidene]pyrrolidine-2,5-dione
C61H54N20O10S2 — CID 160661552
Data last refreshed: (MolForge compound catalog, from PubChem)
About (3E)-3-[(4-anilino-2-methylsulfinylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[(4-anilino-2-methylsulfonylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[[4-anilino-2-[[morpholin-4-yl(phenyl)methyl]amino]pyrazolo[1,5-a][1,3,5]triazin-8-yl]methylidene]pyrrolidine-2,5-dione
(3E)-3-[(4-anilino-2-methylsulfinylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[(4-anilino-2-methylsulfonylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[[4-anilino-2-[[morpholin-4-yl(phenyl)methyl]amino]pyrazolo[1,5-a][1,3,5]triazin-8-yl]methylidene]pyrrolidine-2,5-dione (PubChem CID 160661552) has the molecular formula C61H54N20O10S2 and a molecular weight of 1291.37 g/mol. Its IUPAC name is (3E)-3-[(4-anilino-2-methylsulfinylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[(4-anilino-2-methylsulfonylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[[4-anilino-2-[[morpholin-4-yl(phenyl)methyl]amino]pyrazolo[1,5-a][1,3,5]triazin-8-yl]methylidene]pyrrolidine-2,5-dione.
Molecular Properties
| Compound Name | (3E)-3-[(4-anilino-2-methylsulfinylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[(4-anilino-2-methylsulfonylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[[4-anilino-2-[[morpholin-4-yl(phenyl)methyl]amino]pyrazolo[1,5-a][1,3,5]triazin-8-yl]methylidene]pyrrolidine-2,5-dione |
|---|---|
| PubChem CID | 160661552 |
| Molecular Formula | C61H54N20O10S2 |
| Molecular Weight | 1291.37 g/mol |
| Exact Mass | 1290.38 |
| IUPAC Name | (3E)-3-[(4-anilino-2-methylsulfinylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[(4-anilino-2-methylsulfonylpyrazolo[1,5-a][1,3,5]triazin-8-yl)methylidene]pyrrolidine-2,5-dione;(3E)-3-[[4-anilino-2-[[morpholin-4-yl(phenyl)methyl]amino]pyrazolo[1,5-a][1,3,5]triazin-8-yl]methylidene]pyrrolidine-2,5-dione |
| SMILES | CS(=O)(=O)c1nc(Nc2ccccc2)n2ncc(/C=C3\CC(=O)NC3=O)c2n1.CS(=O)c1nc(Nc2ccccc2)n2ncc(/C=C3\CC(=O)NC3=O)c2n1.O=C1C/C(=C\c2cnn3c(Nc4ccccc4)nc(NC(c4ccccc4)N4CCOCC4)nc23)C(=O)N1 |
| InChI | InChI=1S/C27H26N8O3.C17H14N6O4S.C17H14N6O3S/c36-22-16-19(25(37)30-22)15-20-17-28-35-24(20)32-26(33-27(35)29-21-9-5-2-6-10-21)31-23(18-7-3-1-4-8-18)34-11-13-38-14-12-34;1-28(26,27)17-21-14-11(7-10-8-13(24)20-15(10)25)9-18-23(14)16(22-17)19-12-5-3-2-4-6-12;1-27(26)17-21-14-11(7-10-8-13(24)20-15(10)25)9-18-23(14)16(22-17)19-12-5-3-2-4-6-12/h1-10,15,17,23H,11-14,16H2,(H,30,36,37)(H2,29,31,32,33);2-7,9H,8H2,1H3,(H,19,21,22)(H,20,24,25);2-7,9H,8H2,1H3,(H,19,21,22)(H,20,24,25)/b19-15+;2*10-7+ |
| InChIKey | RLSUGQRCFKLUOR-VFFWHVRPSA-N |
| XLogP | 4.48 |
| TPSA | 379.55 Ų |
| H-Bond Donors | 7 |
| H-Bond Acceptors | 27 |
| Rotatable Bonds | 15 |
| Heavy Atoms | 93 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1291.37 |
| LogP ≤ 5 | 4.48 |
| H-Bond Donors ≤ 5 | 7 |
| H-Bond Acceptors ≤ 10 | 27 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'}, {'alert_name': 'phthalimide', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 160661552 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.